ZRC 3278

Drug Profile

ZRC 3278

Alternative Names: AZD13721412; MMV674253; ZRC-3278

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Medicines for Malaria Venture
  • Developer Zydus Cadila
  • Class Antimalarials; Small molecules
  • Mechanism of Action Vacuolar proton-translocating ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 22 Jun 2017 Preclinical trials in Malaria in India before June 2017 (Zydus Cadila pipeline, June 2017)
  • 27 Sep 2016 Zydus Cadila and Medicines for Malaria Venture collaborate on the development of MMV 674253 for the treatment of malaria
  • 27 Sep 2016 Early research in Malaria in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top